Lyell Immunopharma vs Karius
Side-by-side comparison of AI visibility scores, market position, and capabilities
Lyell Immunopharma develops next-generation CAR-T cell therapies designed to overcome T cell exhaustion and treat solid tumors, the frontier of cell therapy.
About
Lyell Immunopharma is a clinical-stage cell therapy company founded in 2018 by Rick Klausner and publicly traded on Nasdaq. The company focuses on next-generation CAR-T therapies that address the key limitations of first-generation products, particularly the exhaustion and dysfunction of engineered T cells that limits efficacy especially against solid tumors. Lyell has developed proprietary T cell reprogramming technologies including gene overexpression approaches that maintain T cell stemness and fitness during manufacturing and after infusion. The company is applying these technologies to both hematological malignancies and solid tumors in a pipeline of clinical programs. Lyell has established a research collaboration with GlaxoSmithKline to combine cell therapy expertise. While first-generation CAR-T products have demonstrated remarkable responses in blood cancers, Lyell is focused on the much larger unmet need in solid tumors where current CAR-T therapies have shown limited efficacy. The company represents the scientific evolution of the cell therapy field toward more durable and broadly applicable treatments.
Karius raised $409M total including a $100M Series C in May 2024; its genomic blood test detects 1,000+ pathogens at 400+ U.S. hospitals; launched Karius Focus BAL for pneumonia in April 2025.
About
Karius is a Redwood City, CA-based life sciences company founded in 2014 that developed the Karius Test — a single blood draw that uses next-generation sequencing and AI to detect over 1,000 pathogens (bacteria, fungi, viruses, parasites) in seriously ill patients. The test is used when conventional cultures and targeted diagnostics fail, providing clinicians at transplant centers, children''s hospitals, and ICUs with a comprehensive pathogen report within 24 hours.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.